PHARMACY AND THERAPEUTICS (P&T) COMMITTEE
February 8, 2023

The meeting of the Pharmacy and Therapeutics (P&T) Committee of the North Carolina State Health Plan for Teachers and State Employees (the Plan) was called to order at 6:30 P.M. (EST) on Wednesday, February 8, 2023, via webinar, accessible to the public through the Plan’s website. Quorum was present.

MEMBERS PRESENT:
Ghassan Al-Sabbagh, MD, Gastroenterologist/ Hepatologist, Gastroenterology & Hepatology Consultants
John Anderson, MD, MPH, Chief Medical Officer, Duke Primary Care
Jennifer Burch, PharmD, CDE, Owner, Central Compounding Center
David Konanc, MD, Neurologist, Raleigh Neurology Associates
Laura Rachal, MD, Pediatric Infectious Diseases Specialist, University of North Carolina Hospitals
Peter Robie, MD, General Internist, Wake Forest Baptist Community Physicians
Phil Seats, RPh, Retired Pharmacist
Sheel Solomon, MD, Dermatologist, Preston Dermatology and Skin Surgery

MEMBERS ABSENT:
Sundhar Ramalingam, MD, Oncologist, Duke Cancer Center

PLAN & VENDOR STAFF:
Stephanie Craycroft-Andrews, PharmD, BCACP, Sr. Clinical Pharmacist, State Health Plan, Chairperson
Caroline Smart, Sr. Director, Plan Integration, State Health Plan
Sonya Dunn, MPA, BSPH, RN, Sr. Pharmacy Benefits Program Manager, State Health Plan
Renée Jarnigan, RPh, Clinical Advisor, CVS Health

Welcome
The Chairperson welcomed the Committee members and guests to the webinar and performed roll call.

Conflict of Interest Statement
The Chairperson requested that the P&T Committee members review the agenda, which was distributed prior to the meeting, and disclose any actual or potential conflicts of interest with any item on the agenda. No conflicts of interest were noted.

Old Business
The Chairperson asked the P&T Committee members to review the November 2, 2022 P&T Committee Meeting minutes, which were distributed prior to the meeting. There were no additions or corrections to the minutes, so they were approved as is.

Formulary Updates
Ms. Jarnigan also presented CVS Caremark’s Quarterly Formulary Updates, effective April 1, 2023. This included additions to the formulary, utilization management criteria, drug removals, and tier movements.

Ms. Jarnigan and Dr. Craycroft-Andrews identified five new molecular entities that were being removed from CVS’s New-to-Market block and would be available as covered products, along with utilization
management policies that went along with the new products. The new molecular entities being added to the formulary are as follows: CAMZYOS, ENHERTU, LIVTENCITY, ULTOMIRIS, and VOXZOGO.

The Committee also approved proposed utilization management for the new entities including SGM and Specialty QL for CAMZYOS, ULTOMIRIS, and VOXZOGO; SGM for ENHERTU; and Specialty QL for LIVTENCITY.

Ms. Jarnigan then presented other proposed formulary additions, including formulary add-backs and line extensions. The other additions to the formulary are as follows: AMJEVITA, CORTROPHIN GEL, DHIVY, diclofenac powder 50 mg, JATENZO, ketorolac inj 30 mg/ml, levamlodipine, LOREEV XR, METHADONE INJ 10MG/ML, SEZABY INJ, SKYRIZI INJ 180/1.2, TIVICAY PD 5 MG TAB, and XACIATO GEL 2%. Ms. Jarnigan also presented a brief summary of the Humira biosimilar pipeline for informational purposes.

There was no opposition from the Committee members, so the formulary additions and associated utilization management were approved as presented.

Ms. Jarnigan then explained that the Plan has a formulary exclusion exception process that is available to support Plan members who, per their provider, have a medical necessity to remain on an excluded drug. Ms. Jarnigan then reviewed the following sixteen products that will be excluded from the formulary starting on the effective date: SELZENTRY, TARGRETIN, BYSTOLIC, TYVASO DPI, fenofibrate micronized 30mg & 90mg (hyperinflation exclusion), DEPAKOTE*/ DEPAKOTE ER*/ DEPAKOTE SPRINKLE*, DILANTIN* (CAP, CHW, TAB, SUSP), TEGRETOL* (TAB, SUSP)/ TEGRETOL XR*, TRILEPTAL*, GILENYA, CLIMARA, CARBAGLU, CYSTADANE, DALIRESP, ACZONE, and COMBIGAN. Prior use exemptions will be provided to members currently utilizing branded seizure treatments (indicated by an *), so these members will not need to change medications or go through the exceptions process to continue their current medication.

All products being removed have therapeutic alternatives or generic equivalents that are covered as preferred products on the Plan’s custom formulary. There was no opposition from the Committee members, so these product exclusions were approved as presented.

Ms. Jarnigan then identified two branded products, ZOMIG NASAL SPRAY and PERFOROMIST, which will have a change in tier from preferred to non-preferred. There was no opposition from the Committee members, so the formulary uptiers were approved as presented.

New Business
Ms. Jarnigan also presented some utilization information regarding selected targeted therapies (MEK, BRAF, and RET inhibitors) in response to concerns regarding some excluded products (these were shared with the committee ahead of the meeting). Mr. Seats expressed interest in seeing additional data regarding the number of rejected claims for these therapies which have not been approved via the exceptions process, which will be provided at a future time.

Adjourn
The Chairperson addressed the Committee by thanking them for their service and informed them that the next meeting would be held on May 10, 2023 at 6:30 P.M. via webinar. The meeting was adjourned at approximately 7:35 P.M. (EST).
Stephanie Craycroft-Andrews

Stephanie Craycroft-Andrews, Chair